Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Early Biomarker Identified for Future Allergies in Children

By LabMedica International staff writers
Posted on 25 Jul 2011
A marker of inflammatory cells found in the urine of newborn babies was linked to a higher risk of allergic sensitization, nasal eosinophilia and eczema at six years.

Biomarkers predicting development of atopic disease before the onset of symptoms are needed for targeted prevention as well as individualized intervention and treatment. More...


Scientists at the University of Copenhagen, (Denmark), measured the level of urinary eosinophil protein-X (u-EPX), and several other markers of inflammation, in 369 healthy month-old infants. The children were enrolled in a birth cohort study of symptom-free month-old children born to asthmatic mothers. Their blood eosinophil count was also taken at intervals. Nasal eosinophilia was investigated by nasal scraping in the child's sixth year of life, and allergic rhinitis was diagnosed by age six based on interviews of parents and the child's history of symptoms. Asthma-like symptoms and diagnoses of asthma and eczema were also noted.

In the first year of life, 4% of the children developed asthma-like symptoms and 27% were diagnosed with eczema. Another 17% went on to develop asthma-like symptoms and 15% developed eczema by age six. The investigators analyzed the data for associations between infant levels of u-EPX and future symptoms and diagnoses, and found that elevated u-EPX at one month was associated with 49% increase in risk of allergic sensitization, an association that was statistically significant for both food and aeroallergens.

High u-EPX was also associated with a three-fold risk of developing nasal eosinophilia, indicating allergic inflammation of the upper airways. Finally, infants whose u-EPX was in the top quartile had a 40% greater risk for developing eczema by the age of six than those in the lower three quartiles. The u-EPX concentration was determined by a commercial double-antibody radioimmunoassay.

Hans Bisgaard, MD, DMSci, professor of pediatrics at the University of Copenhagen, said, "These data suggest that there is early life eosinophilic activation prior to symptom debut in children developing atopy-related conditions. The mechanism behind the apparent presymptom eosinophilic activation in very young children is still unknown, but this study suggests that there is an ongoing pathogenesis in these children that begins well before symptom onset and includes the activation of eosinophil granulocytes." The study was published online on June 16, 2011 in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

University of Copenhagen




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.